Author Archives: admin


West Coast Stem Cell Clinic, TeleHealth, Now Offering Stem …

Stem cell treatments for back pain from arthritis are now being offered at top West Coast stem cell clinic, TeleHealth. The outpatient, low risk treatments are provided by Board Certified doctors with extensive experience in stem cell therapy.

Orange County, California (PRWEB) December 02, 2013

Stem cell treatments for back pain from arthritis are now being offered at top West Coast stem cell clinic, TeleHealth. The outpatient, low risk treatments are provided by Board Certified doctors with extensive experience in stem cell therapy. For more information and scheduling call (888) 828-4575.

Traditional treatments for arthritic spinal joints involve interventional procedures that do a great job at reducing pain, however, they do not alter the course of the condition. They act as a proverbial "band aid", and are necessary every so often once pain returns.

Stem cell injections, on the other hand, have the potential to provide pain relief while possible regenerating some of the damaged tissue. Initial small studies have shown this potential for cartilage regeneration in animals, while small human studies have demonstrated excellent clinical outcomes.

TeleHealth offers these stem cell injections in an outpatient setting with Board Certified doctors. The injection material is processed from a persons own fat or bone marrow, so there is very little risk of infection or adverse event.

In addition to offering stem cell therapy for back pain, TeleHealth also offers the treatments for extremity joint arthritis in the knee, shoulder, hip, ankle, elbow and wrist. Additionally, tendonitis of the elbow, shoulder, Achilles and knee typically responds very well to the treatments. Non-healing fractures are indicated as well.

For more information and scheduling call (888) 828-4575.

For the original version on PRWeb visit: http://www.prweb.com/releases/stemcellsforbackpain/californiastemcells/prweb11376304.htm

Search BioPortfolio:

Go here to see the original:
West Coast Stem Cell Clinic, TeleHealth, Now Offering Stem ...

[International version] Linda van Laake: "We want to work together to improve stem cell treatment" – Video


[International version] Linda van Laake: "We want to work together to improve stem cell treatment"
Dr Linda van Laake is assistant professor and specialist registrar in Cardiology at the University Medical Center Utrecht and Hubrecht Institute. She carries...

By: UniversiteitUtrecht

Read the original post:
[International version] Linda van Laake: "We want to work together to improve stem cell treatment" - Video

Human Stem Cells Converted to Functional Lung Cells | Columbia …

NEW YORK, NY For the first time, scientists have succeeded in transforming human stem cells into functional lung and airway cells. The advance, reported by Columbia University Medical Center (CUMC) researchers, has significant potential for modeling lung disease, screening drugs, studying human lung development, and, ultimately, generating lung tissue for transplantation. The study was published today in the journal Nature Biotechnology.

Human embryonic stem cells differentiated into type II alveolar lung epithelial cells (green). A large portion of these transformed cells express surfactant protein B (red), which indicates that they are functional type II cells. Image credit: Sarah Xuelian Huang, PhD at the Columbia Center for Translational Immunology at CUMC.

Researchers have had relative success in turning human stem cells into heart cells, pancreatic beta cells, intestinal cells, liver cells, and nerve cells, raising all sorts of possibilities for regenerative medicine, said study leader Hans-Willem Snoeck, MD, PhD, professor of medicine (in microbiology & immunology) and affiliated with the Columbia Center for Translational Immunology and the Columbia Stem Cell Initiative. Now, we are finally able to make lung and airway cells. This is important because lung transplants have a particularly poor prognosis. Although any clinical application is still many years away, we can begin thinking about making autologous lung transplantsthat is, transplants that use a patients own skin cells to generate functional lung tissue.

The research builds on Dr. Snoecks 2011 discovery of a set of chemical factors that can turn human embryonic stem (ES) cells or human induced pluripotent stem (iPS) cells into anterior foregut endodermprecursors of lung and airway cells. (Human iPS cells closely resemble human ES cells but are generated from skin cells, by coaxing them into taking a developmental step backwards. Human iPS cells can then be stimulated to differentiate into specialized cellsoffering researchers an alternative to human ES cells.)

In the current study, Dr. Snoeck and his colleagues found new factors that can complete the transformation of human ES or iPS cells into functional lung epithelial cells (cells that cover the lung surface). The resultant cells were found to express markers of at least six types of lung and airway epithelial cells, particularly markers of type 2 alveolar epithelial cells. Type 2 cells are important because they produce surfactant, a substance critical to maintain the lung alveoli, where gas exchange takes place; they also participate in repair of the lung after injury and damage.

The findings have implications for the study of a number of lung diseases, including idiopathic pulmonary fibrosis (IPF), in which type 2 alveolar epithelial cells are thought to play a central role. No one knows what causes the disease, and theres no way to treat it, says Dr. Snoeck. Using this technology, researchers will finally be able to create laboratory models of IPF, study the disease at the molecular level, and screen drugs for possible treatments or cures.

In the longer term, we hope to use this technology to make an autologous lung graft, Dr. Snoeck said. This would entail taking a lung from a donor; removing all the lung cells, leaving only the lung scaffold; and seeding the scaffold with new lung cells derived from the patient. In this way, rejection problems could be avoided. Dr. Snoeck is investigating this approach in collaboration with researchers in the Columbia University Department of Biomedical Engineering.

I am excited about thiscollaboration with Hans Snoeck, integrating stem cell science withbioengineering in the search for new treatments for lung disease, said Gordana Vunjak-Novakovic, PhD, co-author of the paper and Mikati Foundation Professor of Biomedical Engineering at Columbias Engineering School and professor of medical sciences at Columbia University College of Physicians and Surgeons.

The paper is titled, Highly efficient generation of airway and lung epithelial cells from human pluripotent stem cells.

The other contributors are Sarah X.L. Huang, Mohammad Naimul Islam, John ONeill, Zheng Hu, Yong-Guang Yang, Ya-Wen Chen, Melanie Mumau, Michael D. Green, and Jahar Bhattacharya (all at CUMC).

Read the original here:
Human Stem Cells Converted to Functional Lung Cells | Columbia ...

Stem Cell Treatments for Chronic Bronchitis in 2013 |

Overview: What Are Stem Cell Treatments for Chronic Bronchitis?

Stem cell treatments for chronic bronchitis are one of the latest advancements in chronic bronchitis treatments available today, and are being utilized in clinical settings around the world. Once considered an alternative form of treatment for chronic bronchitis and other forms of lung disease, stem cell therapies for chronic bronchitis are becoming increasingly more common as they provide consistent positive results for patients suffering from mild, moderate, and severe forms of chronic bronchitis. Stem cells and other forms of regenerative medicine are helping people improve their quality of life and breathe easier.

Adipose (Fat-Derived) Stem Cell Procedure & Venous (Blood-Derived) Stem Cell Procedure for Chronic Bronchitis

Lung Institute utilizes adult autologous stem cells, derived from the patients own body, for the adipose (fat-derived) stem cell procedure and the venous (blood-derived) stem cell procedure. These stem cells are extracted, isolated, and immediately reintroduced to the affected lung tissue, where they then divide and replicate into healthy cells specialized to that tissue. The use of autologous stem cells in transplantation is considered to be more reliable than stem cells from another individual as there is a much lower probability of rejection. Both adipose stem cells and venous stem cells have shown anti-inflammatory properties beneficial to patients with lung disease.

Adult stem cells have the ability to self-renew indefinitely, meaning they have the capability to divide many times and specialize in the repair of damaged organs while still sustaining the original undifferentiated cell. The adipose procedure is always performed in conjunction with the venous procedure, while the venous procedure may be chosen to be performed on its own depending on the nature of the patients condition and health history.

Lung Institute does not use any type of embryonic or fetal stem cells in their procedures.

Autologous Mesenchymal Stem Cells

During the adipose procedure human mesenchymal stem cells (hMSCs) are extracted from the patients adipose tissue. hMSCs are immune-modulatory and versatile due to their secreted bioactive molecules, giving them anti-inflammatory and regenerative properties. Because of this, these highly specialized cells have the potential orchestrate the complex reparative processes needed to restore diseased lung tissues. Human mesenchymal stem cells are not only utilized in the restoration of damage lung tissue, but are also capable of regenerating into multiple phenotypes, including cells capable of forming bone, cartilage, muscle, marrow, tendon/ligament, adipocytes (adipose tissue) and connective tissue.

As a result of hMSCs intrinsic capability to differentiate into various phenotypes of mature cells while secreting cytokines and natural growth factors at the site of tissue damage, they have significant therapeutic capacity in sufferers of chronic bronchitis.

In the adipose procedure, following the extraction of hMSCs from fat tissue, hematopoetic stem cells are also extracted through the use of an IV. Both types of stem cells are then washed and separated in the lab. They are then immediately inserted into the patients body intravenously once again for the molecular cueing of regenerative pathways in damaged lung tissues.

Read the rest here:
Stem Cell Treatments for Chronic Bronchitis in 2013 |

Stem cell doctor, Zannos Grekos leading stem cell doctors

Dr. Zannos Grekos is one of the few pioneers among American stem cell doctors. Based in Southwest Florida, his stem cell clinic walks each patient through the stem cell surgery process with care. While the treatment is not administered in the USA, there are hopes on the horizon that eventually stem cell surgery in the USA will become possible.

See how this stem cell company eases their patients through procedures with care.

For now, stem cell clinics in America begin the pre-operational procedure and then move to a state-of-the-art facility in the Dominican Republic to complete the cell transplants. Stem cell treatments clinics will draw the patient's blood and then transport it to a laboratory where clinicians begin to grow additional stem cells from the patient's blood. The next phase of the process is the actual stem cell surgery where the cells are inserted back into the body to enhance the affected area.

Watch patient stories HERE and see how American stem cell doctors are introducing radically simple procedures.

Stem cell doctors in the USA are beginning to support stem cell surgery. Stem cell doctors such as Zannos Grekos are excited to be helping patients at their stem cell therapy clinics using stem cell production for patients with both heart and lung diseases. Stem cell companies are also studying therapy for other diseases as well.

Curious to see what stem cell doctors are up to? Stem cell clinics in America are committed to researching the best and safest measures to help their patients. At Regenocyte, Dr. Grekos and his stem cell company specialize in research and implementation of stem cell regeneration.

Discover more about stem cell clinics today.

For Search Engines only: stem cell clinics, stem cell clinics in use, stem cell doctors, stem cell clinics in America, stem cell treatment clinics, stem cell doctors in the USA, American stem cell doctors, stem cell surgery in USA, stem cell surgery, stem cell therapy clinics, stem cell companies, stem cell company

See original here:
Stem cell doctor, Zannos Grekos leading stem cell doctors

Stem Cells – Types, Uses, and Therapies – MedicineNet

What are stem cells?

Stem cells are cells that have the potential to develop into many different or specialized cell types. Stem cells can be thought of as primitive, "unspecialized" cells that are able to divide and become specialized cells of the body such as liver cells, muscle cells, blood cells, and other cells with specific functions. Stem cells are referred to as "undifferentiated" cells because they have not yet committed to a developmental path that will form a specific tissue or organ. The process of changing into a specific cell type is known as differentiation. In some areas of the body, stem cells divide regularly to renew and repair the existing tissue. The bone marrow and gastrointestinal tract are examples areas in which stem cells function to renew and repair tissue.

The best and most readily understood example of a stem cell in humans is that of the fertilized egg, or zygote. A zygote is a single cell that is formed by the union of a sperm and ovum. The sperm and the ovum each carry half of the genetic material required to form a new individual. Once that single cell or zygote starts dividing, it is known as an embryo. One cell becomes two, two become four, four become eight, eight to sixteen, and so on; doubling rapidly until it ultimately creates the entire sophisticated organism. That organism, a person, is an immensely complicated structure consisting of many, many, billions of cells with functions as diverse as those of your eyes, your heart, your immune system, the color of your skin, your brain, etc. All of the specialized cells that make up these body systems are descendants of the original zygote, a stem cell with the potential to ultimately develop into all kinds of body cells. The cells of a zygote are totipotent, meaning that they have the capacity to develop into any type of cell in the body.

The process by which stem cells commit to become differentiated, or specialized, cells is complex and involves the regulation of gene expression. Research is ongoing to further understand the molecular events and controls necessary for stem cells to become specialized cell types.

Stem Cells - Experience Question: Please describe your experience with stem cells.

Stem Cells - Umbilical Cord Question: Have you had your child's umbilical cord blood banked? Please share your experience.

Stem Cells - Available Therapies Question: Did you or someone you know have stem cell therapy? Please discuss your experience.

Medical Author:

Melissa Conrad Stppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology.

Medical Editor:

View post:
Stem Cells - Types, Uses, and Therapies - MedicineNet

Human stem cells converted to functional lung cells

PUBLIC RELEASE DATE:

1-Dec-2013

Contact: Karin Eskenazi ket2116@cumc.columbia.edu 212-342-0508 Columbia University Medical Center

NEW YORK, NY For the first time, scientists have succeeded in transforming human stem cells into functional lung and airway cells. The advance, reported by Columbia University Medical Center (CUMC) researchers, has significant potential for modeling lung disease, screening drugs, studying human lung development, and, ultimately, generating lung tissue for transplantation. The study was published today in the journal Nature Biotechnology.

"Researchers have had relative success in turning human stem cells into heart cells, pancreatic beta cells, intestinal cells, liver cells, and nerve cells, raising all sorts of possibilities for regenerative medicine," said study leader Hans-Willem Snoeck, MD, PhD, professor of medicine (in microbiology & immunology) and affiliated with the Columbia Center for Translational Immunology and the Columbia Stem Cell Initiative. "Now, we are finally able to make lung and airway cells. This is important because lung transplants have a particularly poor prognosis. Although any clinical application is still many years away, we can begin thinking about making autologous lung transplantsthat is, transplants that use a patient's own skin cells to generate functional lung tissue."

The research builds on Dr. Snoeck's 2011 discovery of a set of chemical factors that can turn human embryonic stem (ES) cells or human induced pluripotent stem (iPS) cells into anterior foregut endodermprecursors of lung and airway cells. (Human iPS cells closely resemble human ES cells but are generated from skin cells, by coaxing them into taking a developmental step backwards. Human iPS cells can then be stimulated to differentiate into specialized cellsoffering researchers an alternative to human ES cells.)

In the current study, Dr. Snoeck and his colleagues found new factors that can complete the transformation of human ES or iPS cells into functional lung epithelial cells (cells that cover the lung surface). The resultant cells were found to express markers of at least six types of lung and airway epithelial cells, particularly markers of type 2 alveolar epithelial cells. Type 2 cells are important because they produce surfactant, a substance critical to maintain the lung alveoli, where gas exchange takes place; they also participate in repair of the lung after injury and damage.

The findings have implications for the study of a number of lung diseases, including idiopathic pulmonary fibrosis (IPF), in which type 2 alveolar epithelial cells are thought to play a central role. "No one knows what causes the disease, and there's no way to treat it," says Dr. Snoeck. "Using this technology, researchers will finally be able to create laboratory models of IPF, study the disease at the molecular level, and screen drugs for possible treatments or cures."

"In the longer term, we hope to use this technology to make an autologous lung graft," Dr. Snoeck said. "This would entail taking a lung from a donor; removing all the lung cells, leaving only the lung scaffold; and seeding the scaffold with new lung cells derived from the patient. In this way, rejection problems could be avoided." Dr. Snoeck is investigating this approach in collaboration with researchers in the Columbia University Department of Biomedical Engineering.

"I am excited about this collaboration with Hans Snoeck, integrating stem cell science with bioengineering in the search for new treatments for lung disease," said Gordana Vunjak-Novakovic, co-author of the paper and Mikati Foundation Professor of Biomedical Engineering at Columbia's Engineering School and professor of medical sciences at Columbia University College of Physicians and Surgeons.

Read the rest here:
Human stem cells converted to functional lung cells

Cell Medicine – Cognizant Communication Corporation

Aims & Scope

The importance of translatingoriginal, peer-reviewed research and review articles on the subject of cell therapy and its application to human diseases to societyhas led to the formation ofthe journalCell Medicine. To ensure high-quality contributions from all areas of transplantation, the same rigorous peer review will be applied to articles published in Cell Medicine. Articles may deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, and stem cells, among others. Basic clinical studies and immunological research papers may also be featured if they have a translational interest. To provide complete coverage of this revolutionary field, Cell Medicine will report on relevant technological advances and their potential for translational medicine. Cell Medicine will be a purely online Open Access journal. There will therefore be an inexpensive publication charge, which is dependent on the number of pages, in addition to the charge for color figures. This will allow your work to be disseminated to a wider audience and also entitle you to a free PDF, as well as prepublication of an unedited version of your manuscript.

Cell Medicine features:

Original Contributions: Peer-reviewed, high-quality research investigations that represent new and significant contributions to science. Review Articles: Reviews of major areas in cellular transplantation. These may be of any length and are peer reviewed. Brief Communications: Timely and brief peer-reviewed studies. Letters to the Editor: Readers' comments on journal articles and other matters of interest to transplant researchers. Announcements and News: Notices of upcoming meetings, conferences, seminars, and other events of interest to those in the field.

Submission Requirements: From the beginning of November 2009, authors are requested to submit the original manuscript (and revised manuscript if needed) via our ManuscriptCentral websiteat http://mc.manuscriptcentral.com/cogcom-ct.

Please include a cover letter, specifying your intent to submit to Cell Medicine, as well as containing the name, address, telephone, and fax number, and electronic mail address of the author responsible for correspondence. Follow the General Form guidelines below to prepare the manuscript, figures, and tables.

At the time of submission you will be asked to confirm that you will pay the relatively inexpensive open access fees ($900 for less than 5 pages, $1800 for 5-12 pages and +$75 for each additional page) when billed. In addition, there are sections for detailing any conflicts of interest and financial support and that you (as corresponding/submitting author) have the permission of the other authors to submit the manuscript. You will be given the option of which section of the editorial office to submit to. Here you would select Cell Medicine.

There will also be a $105 submission fee.

On receipt of your manuscript, it will be checked to ensure that it is correctly formatted.

When the manuscript is accepted for publication, the author(s) will be required to provide two hard copies of the manuscript, two high-quality copies of all artwork, and a CD or disk (no zip disks) (see Final Accepted Manuscript/Disk below). Information on where to mail the final hard copy, figures, and CD/disk will be provided in an acceptance letter. Manuscripts are accepted for consideration with the understanding that they have not been published elsewhere except in abstract form and are not concurrently under review elsewhere.

View post:
Cell Medicine - Cognizant Communication Corporation

Embryonic stem cell – Wikipedia, the free encyclopedia

Embryonic stem cells (ES cells) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage embryo.[1] Human embryos reach the blastocyst stage 45 days post fertilization, at which time they consist of 50150 cells. Isolating the embryoblast or inner cell mass (ICM) results in destruction of the fertilized human embryo, which raises ethical issues. Those issues include whether or not human lives at the embryonic stage should be granted the moral status of other human beings.[2][3]

Human ES cells measure approximately 14m while mouse ES cells are closer to 8m.[4]

Embryonic stem cells are distinguished by two distinctive properties:

ES cells are pluripotent, that is, they are able to differentiate into all derivatives of the three primary germ layers: ectoderm, endoderm, and mesoderm. These include each of the more than 220 cell types in the adult body. Pluripotency distinguishes embryonic stem cells from adult stem cells found in adults; while embryonic stem cells can generate all cell types in the body, adult stem cells are multipotent and can produce only a limited number of cell types.

Additionally, under defined conditions, embryonic stem cells are capable of propagating themselves indefinitely. This allows embryonic stem cells to be employed as useful tools for both research and regenerative medicine, because they can produce limitless numbers of themselves for continued research or clinical use.

Because of their plasticity and potentially unlimited capacity for self-renewal, ES cell therapies have been proposed for regenerative medicine and tissue replacement after injury or disease. Diseases that could potentially be treated by pluripotent stem cells include a number of blood and immune-system related genetic diseases, cancers, and disorders; juvenile diabetes; Parkinson's; blindness and spinal cord injuries. Besides the ethical concerns of stem cell therapy (see stem cell controversy), there is a technical problem of graft-versus-host disease associated with allogeneic stem cell transplantation. However, these problems associated with histocompatibility may be solved using autologous donor adult stem cells, therapeutic cloning, stem cell banks or more recently by reprogramming of somatic cells with defined factors (e.g. induced pluripotent stem cells). Other potential uses of embryonic stem cells include investigation of early human development, study of genetic disease and as in vitro systems for toxicology testing.

According to a 2002 article in PNAS, "Human embryonic stem cells have the potential to differentiate into various cell types, and, thus, may be useful as a source of cells for transplantation or tissue engineering."[6]

Current research focuses on differentiating ES into a variety of cell types for eventual use as cell replacement therapies (CRTs). Some of the cell types that have or are currently being developed include cardiomyocytes (CM), neurons, hepatocytes, bone marrow cells, islet cells and endothelial cells.[7] However, the derivation of such cell types from ESs is not without obstacles and hence current research is focused on overcoming these barriers. For example, studies are underway to differentiate ES in to tissue specific CMs and to eradicate their immature properties that distinguish them from adult CMs.[8]

Besides in the future becoming an important alternative to organ transplants, ES are also being used in field of toxicology and as cellular screens to uncover new chemical entities (NCEs) that can be developed as small molecule drugs. Studies have shown that cardiomyocytes derived from ES are validated in vitro models to test drug responses and predict toxicity profiles.[7] ES derived cardiomyocytes have been shown to respond to pharmacological stimuli and hence can be used to assess cardiotoxicity like Torsades de Pointes.[9]

ES-derived hepatocytes are also useful models that could be used in the preclinical stages of drug discovery. However, the development of hepatocytes from ES has proven to be challenging and this hinders the ability to test drug metabolism. Therefore, current research is focusing on establishing fully functional ES-derived hepatocytes with stable phase I and II enzyme activity.[10]

More here:
Embryonic stem cell - Wikipedia, the free encyclopedia